60 Degrees Pharmaceuticals (SXTP) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 15, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Information [Line Items]
Entity Registrant Name	60 DEGREES PHARMACEUTICALS, INC.
Entity Central Index Key	0001946563
Entity File Number	001-41719
Entity Tax Identification Number	45-2406880
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1025 Connecticut Avenue
Entity Address, Address Line Two	NW Suite 1000
Entity Address, City or Town	Washington, D.C.
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	20036
Entity Phone Fax Numbers [Line Items]
City Area Code	(202)
Local Phone Number	327-5422
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		12,142,116
Common Stock, par value $0.0001 per share
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	SXTP
Security Exchange Name	NASDAQ
Warrants, each warrant to purchase one share of Common Stock
Entity Listings [Line Items]
Title of 12(b) Security	Warrants, each warrant to purchase one share of Common Stock
Trading Symbol	SXTPW
Security Exchange Name	NASDAQ

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 2,894,700	$ 2,142,485
Accounts Receivable	316,220	231,332
Prepaid and Other Assets	4,259,511	4,402,602
Inventory (Note 3)	435,377	466,169
Total Current Assets	7,905,808	7,242,588
Property and Equipment, net (Note 4)	57,354	57,761
Other Assets:
Right of Use Asset (Note 11)		13,517
Long-Term Prepaid Expense	198,529	242,647
Intangible Assets, net (Note 5)	217,417	227,258
Total Other Assets	415,946	483,422
Total Assets	8,379,108	7,783,771
Current Liabilities:
Accounts Payable and Accrued Expenses	529,449	506,206
Lease Liability (Note 11)		13,650
SBA EIDL (including accrued interest) (Note 7)	8,772	8,772
Derivative Liabilities (Note 8)	565,949	2,306,796
Total Current Liabilities:	1,104,170	2,835,424
Long-Term Liabilities:
SBA EIDL (including accrued interest) (Note 7)	149,460	150,251
Total Long-Term Liabilities	149,460	150,251
Total Liabilities	1,253,630	2,985,675
Commitments and Contingencies (Note 11)
SHAREHOLDERS’ EQUITY:
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 78,803 and 78,803 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (Note 6)	9,858,040	9,858,040
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 11,570,578 and 5,810,089 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively (Note 6)	1,176	581
Additional Paid-in Capital	29,359,498	27,456,802
Accumulated Other Comprehensive Income	131,667	135,561
Accumulated Deficit	(32,150,380)	(32,580,850)
60P Shareholders’ Equity:	7,200,001	4,870,134
Noncontrolling Interest	(74,523)	(72,038)
Total Shareholders’ Equity	7,125,478	4,798,096
Total Liabilities and Shareholders’ Equity	$ 8,379,108	$ 7,783,771

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	11,762,578	5,810,089
Common stock, shares outstanding	11,762,578	5,810,089
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	78,803	78,803
Preferred stock, shares outstanding	78,803	78,803

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Product and Service Revenues, net	$ 116,463	$ 17,172
Cost of Revenues	65,437	73,120
Gross Profit (Loss)	51,026	(55,948)
Research Revenues	29,631	4,292
Net Revenue (Loss)	80,657	(51,656)
Operating Expenses
Research and Development	337,182	123,994
General and Administrative Expenses	1,075,134	775,014
Total Operating Expenses	1,412,316	899,008
Loss from Operations	(1,331,659)	(950,664)
Interest Expense	(1,402)	(1,141,429)
Change in Fair Value of Derivative Liabilities	1,740,847	(5,134)
Loss on Debt Extinguishment		(839,887)
Change in Fair Value of Promissory Note		339,052
Other Income	20,262	591
Total Interest and Other Income (Expense), net	1,759,707	(1,646,807)
Net Income (Loss) before Provision for Income Taxes	428,048	(2,597,471)
Provision for Income Taxes (Note 9)	63	63
Net Income (Loss) including Noncontrolling Interest	427,985	(2,597,534)
Net (Loss) Gain – Noncontrolling Interest	(2,485)	2,527
Net Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc.	430,470	(2,600,061)
Comprehensive Income (Loss):
Net Income (Loss)	427,985	(2,597,534)
Unrealized Foreign Currency Translation Loss	(3,894)	(1,290)
Total Comprehensive Income (Loss)	424,091	(2,598,824)
Net (Loss) Gain – Noncontrolling Interest	(2,485)	2,527
Comprehensive Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc.	426,576	(2,601,351)
Cumulative Dividends on Series A Preferred Stock	(117,881)
Net Income (Loss) - attributed to Common Stockholders	$ 308,695	$ (2,601,351)
Net Income (Loss) per Common Share
Basic (in Dollars per share)	$ 0.03	$ (1.13)
Weighted Average Number of Common Shares Outstanding
Basic (in Shares)	10,124,517	2,304,131
Product Revenues – net of Discounts and Rebates
Product and Service Revenues, net	$ 105,674	$ 17,172
Service Revenues
Product and Service Revenues, net	$ 10,789

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Diluted	$ 0.03	$ (1.13)
Net Loss per Common Share,Diluted	10,124,517	2,304,131

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders’ Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock Series A	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Shareholders ’Equity (Deficit) Attributable to 60P	Noncontrolling Interest on Shareholders	Total
Balance at Dec. 31, 2022		$ 239	$ 5,164,461	$ (28,815,148)	$ 73,708	$ (23,576,740)	$ (572,320)	$ (24,149,060)
Balance (in Shares) at Dec. 31, 2022		2,386,009
Cancellation of common stock		$ (145)	145
Cancellation of common stock (in Shares)		(1,451,000)
Share-based compensation to vendors for services		$ 144	5,378,764			5,378,908		$ 5,378,908
Share-based compensation to vendors for services (in Shares)		1,443,000
Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (in Shares)								930,000
Net foreign translation loss					(1,290)	(1,290)		$ (1,290)
Net income (loss)				(2,600,061)		(2,600,061)	2,527	(2,597,534)
Balance at Mar. 31, 2023		$ 238	10,543,370	(31,415,209)	72,418	(20,799,183)	(569,793)	(21,368,976)
Balance (in Shares) at Mar. 31, 2023		2,378,009
Balance at Dec. 31, 2023	$ 9,858,040	$ 581	27,456,802	(32,580,850)	135,561	4,870,134	(72,038)	4,798,096
Balance (in Shares) at Dec. 31, 2023	78,803	5,810,089
Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs		$ 526	1,897,770			1,898,296		$ 1,898,296
Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (in Shares)		5,260,951						0
Issuance of common stock upon exercise of Pre-Funded Warrants		$ 50	4,945			4,995		$ 4,995
Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares)		499,538
Issuance of shares for RSUs		$ 19	(19)
Issuance of shares for RSUs (in Shares)		192,000
Net foreign translation loss					(3,894)	(3,894)		(3,894)
Net income (loss)				430,470		430,470	(2,485)	427,985
Balance at Mar. 31, 2024	$ 9,858,040	$ 1,176	$ 29,359,498	$ (32,150,380)	$ 131,667	$ 7,200,001	$ (74,523)	$ 7,125,478
Balance (in Shares) at Mar. 31, 2024	78,803	11,762,578

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ 427,985	$ (2,597,534)
Adjustments to Reconcile Net Income (Loss) to Net Cash Used in Operating Activities:
Depreciation	407	6,901
Amortization	8,207	7,175
Amortization of Debt Discount		343,510
Amortization of ROU Asset	13,517	12,427
Amortization of Note Issuance Costs		31,757
Amortization of Capitalized Share-Based Payments	125,368	320,825
Share-Based Compensation to Vendors for Services		212,605
Loss on Debt Extinguishment		839,887
Change in Fair Value of Derivative Liabilities	(1,740,847)	5,134
Change in Fair Value of Promissory Note		(339,052)
Write-offs of Capitalized Patents	8,378
Inventory Reserve		4,205
Changes in Operating Assets and Liabilities:
Accounts Receivable	(84,888)	(36,890)
Prepaid and Other Assets	61,841	18,020
Inventory	30,792	(108,082)
Accounts Payable and Accrued Liabilities	23,243	77,038
Accrued Interest	(791)	761,643
Reduction of Lease Liability	(13,650)	(12,247)
Deferred Compensation		40,000
Net Cash Used in Operating Activities	(1,140,438)	(412,678)
CASH FLOWS FROM INVESTING ACTIVITIES
Capitalization of Patents	(726)	(3,292)
Acquisition of Intangibles	(9,088)
Net Cash Used in Investing Activities	(9,814)	(3,292)
CASH FLOWS FROM FINANCING ACTIVITIES
Net Proceeds from Common Stock and Warrants Offering	1,914,513
Payment of Deferred Offering Costs	(16,217)	(17,612)
Proceeds from Exercise of Pre-Funded Warrants	4,995
Proceeds from Advances - Related Party		200,000
Net Cash Provided by Financing Activities	1,903,291	182,388
Effect of Exchange Rate Changes on Cash	(824)	(1,290)
Change in Cash	752,215	(234,872)
Cash—Beginning of Period	2,142,485	264,865
Cash—End of Period	2,894,700	29,993
NONCASH INVESTING/FINANCING ACTIVITIES
Capitalized Share-Based Payments to Vendors		4,908,658
Fair Value of Warrants Issued to Underwriters	71,364
Additions to ROU Assets for Lease Renewal		50,922
Additions to Lease Liabilities for Lease Renewal		50,570
Stock Issued for Payment of Deferred Compensation		325,000
Stock Issued for Acquisition of Intangibles		$ 33,895

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2024
Nature of Operations [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. (a) Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028). The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, equal to 110% of the offering price per unit (the “IPO Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. (b) Risks and Uncertainties The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition. In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability to pursue its business strategy. (c) Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued. In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. On March 31, 2024, the Company had cash and cash equivalents totaling $2,894,700, as compared to cash and cash equivalents totaling $2,142,485 at December 31, 2023. During the three months ended March 31, 2024, the Company used $1,140,438 of cash in its operating activities. The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, proceeds from the issuance of convertible debt, and borrowings under loan and security agreements. The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated condensed financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself. The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments. The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772 and $529,449 to satisfy current accounts payable and accrued expenses.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended December 31, 2023 and 2022, included in the Company’s annual report on Form 10-K, as filed with the SEC on April 1, 2024 (the “Annual Report”). Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Annual Report have been omitted. (b) Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated condensed financial statements. (c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, derivative liabilities, and valuation allowance for the deferred tax asset. (d) Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor, and a large American pharmaceutical distributor. There was no allowance as of March 31, 2024 and December 31, 2023. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. At March 31, 2024, the US government accounted for none of the outstanding accounts receivable balance (13% at December 31, 2023) and the American pharmaceutical distributor accounted for 99% of the outstanding accounts receivable balance (79% for the year ended December 31, 2023). (e) Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). During the three months ended March 31, 2024, write-downs for expired inventory totaled $641 ($5,391 for the three months ended March 31, 2023). (f) Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of March 31, 2024, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date. (g) Equity-Classified Warrants As of March 31, 2024, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding. (h) Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At March 31, 2024, significant customers represented 99% of receivables (consisting of two customers and one significant customer at 99%). At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively). For the three months ended March 31, 2024, 90% of total net revenues (consisting of three customers and one significant customer at 90%) were generated from significant customers. For the three months ended March 31, 2023, 100% of total net revenues (consisting of two significant customers at 212% and (112%), respectively) were generated from significant customers. Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). (i) Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, since its inception, the Company has managed its business in one identifiable segment. (j) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. (k) Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $337,182 in research and development expense during the three months ended March 31, 2024 ($123,994 for the three months ended March 31, 2023). (l) Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Condensed Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). Changes in fair value related to credit risk are recognized in Other Comprehensive Income (Loss). As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 7 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at March 31, 2024, and December 31, 2023 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 8 for more information on Derivative Liabilities. Liabilities measured at fair value at March 31, 2024 and December 31, 2023 are as follows: March 31, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 565,949 $ 565,949 Total $ - $ - $ 565,949 $ 565,949 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. A rollforward of liabilities measured at fair value using Level 3 inputs for the three months ended March 31, 2024 and 2023 are presented in Note 7 (Debt) and Note 8 (Derivative Liabilities), respectively. (m) Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of March 31, 2024, and December 31, 2023, the fair value of Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities. (n) Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements. For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain or Loss. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months ended As of Currency 2024 2023 March 31, December 31, 1 AUD = 0.66 USD 0.68 USD 0.65 USD 0.68 USD (o) Reclassifications Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive income (loss), shareholders’ equity (deficit), or cash flows. (p) Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 10. The Company accounts for share-based payments in accordance with ASC Subtopic 718, Compensation – Stock Compensation The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 10 for further details. (q) Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. (r) Net Income (Loss) per Common Share Net Income (Loss) per Common Share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company has included the Pre-Funded Warrants issued in January 2024 (See Note 6) in its computation of basic and diluted net income (loss) per share due to the nominal exercise price of $0.01 per share. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss or a reduction of net income in determining basic and diluted net income (loss) attributable to common stockholders. As the Company reported a net loss for the three months ended March 31, 2023, the calculation of diluted net loss per common share is the same as basic net loss per common share. For the three months ended March 31, 2024, all securities that could potentially dilute basic earnings per share in the future have been excluded from the diluted calculation because the effect would be antidilutive. The potential dilutive securities for the three months ended March 31, 2024 include 10,617,657 common stock warrants and 37,736 unexercised stock options granted under the 2022 Plan. (s) Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. (t) Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through May 15, 2024, which is the date the financial statements were issued. See Note 12. (u) Recently Adopted and Issued Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company’s financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. The ASU also requires entities with a single reportable segment to provide all segment disclosures under ASC 280, including the new required disclosures under the ASU. The ASU is effective for all public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The ASU must be applied retrospectively. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statement disclosures.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2024
Inventory [Abstract]
INVENTORY	3. INVENTORY Inventory consists of the following major classes: March 31, December 31, Work in Process $ 278,987 $ 278,987 Finished Goods 156,390 187,182 Inventory 435,377 466,169

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2024
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT As of March 31, 2024 and December 31, 2023, Property and Equipment, net consists of: March 31, December 31, 2024 2023 Lab Equipment $ 132,911 $ 132,911 Machinery 55,800 55,800 Computer Equipment 14,084 14,084 Furniture 3,030 3,030 Property and Equipment, at cost 205,825 205,825 Accumulated Depreciation (148,471 ) (148,064 ) Property and Equipment, Net $ 57,354 $ 57,761 Machinery totaling $55,800 has not yet been placed into service and therefore depreciation has not commenced as of March 31, 2024. Depreciation expense for the three months ended March 31, 2024 and 2023 was in the amount of $407 and $6,901, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2024
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS As of March 31, 2024 and December 31, 2023, Intangible Assets, net consist of: March 31, December 31, Patents $ 174,614 $ 185,595 Website Development Costs 88,336 79,248 Intangible Assets, at cost 262,950 264,843 Accumulated Amortization (45,533 ) (37,585 ) Intangible Assets, net $ 217,417 $ 227,258 During the three months ended March 31, 2024 and 2023, the Company capitalized website development related costs of $9,088 and $33,895, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www. 60degreespharma.com. Amortization expense for the three months ended March 31, 2024, and 2023 was in the amount of $8,207 and $7,175, respectively. During the three months ended March 31, 2024, write-downs for expired or obsolete patents totaled $8,378 ( $0 The following table summarizes the estimated future amortization expense for our patents and website development costs as of March 31, 2024: Period Patents Website 2024 (remaining nine months) $ 4,959 $ 19,812 2025 6,612 23,303 2026 6,612 3,974 2027 6,612 - Thereafter 55,279 - Total $ 80,074 $ 47,089 The Company has recorded $83,830 in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded. In addition, $9,088 in capitalized website development costs will begin amortization when the associated upgrades and enhancements become ready for their intended use.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity [Abstract]
STOCKHOLDERS’ EQUITY	6. STOCKHOLDERS’ EQUITY Pursuant to the Certificate of Incorporation of 60 Degrees Pharmaceuticals, Inc., the Company’s authorized shares consist of (a) 150,000,000 shares of common stock, par value $0.0001 per share and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share, of which 80,965 have been designated as Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”). As of March 31, 2024, 11,762,578 shares of Common Stock and 78,803 shares of Series A Preferred Stock are issued and outstanding. (a) Common Stock In January and March 2023, the Board of Directors, with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 192,101 shares of common stock issued to Tyrone Miller and 1,258,899 shares of common stock issued to the Geoffrey S. Dow Revocable Trust to allow the Company to issue new shares to vendors in exchange for valuable services to be provided for use in the Company’s operations. The cancelled shares represented approximately 61% of the issued and outstanding shares as of December 31, 2022. In January and March 2023, the Company issued a total of 1,443,000 shares of common stock to certain vendors as payment for services rendered or to be provided to the Company. On January 29, 2024, the Company, entered into an Underwriting Agreement with WallachBeth Capital LLC (the “Underwriting Agreement”), relating to the Company’s public offering (the “January 2024 Offering”) of 5,260,901 units (the “Units”) at an offering price of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at an offering price of $0.375 per Pre-Funded Unit. Each Unit consisted of one share of common stock and one warrant exercisable for one share of common stock (the “Warrants”). Each Warrant has an exercise price of $0.4235 per share (110% of the offering price per Unit), is exercisable immediately upon issuance and expires five years from the date of issuance. Each Pre-Funded Unit consists of one pre-funded warrant exercisable for one share of common stock (the “Pre-Funded Warrant”) and one warrant identical to the Warrants included in the Units. The purchase price of each Pre-Funded Unit was equal to the price per Unit sold to the public in the offering, minus $0.01, and the exercise price of each Pre-Funded Warrant is $0.01 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Company granted WallachBeth Capital LLC an option, exercisable within 45 days after the closing of the offering, to purchase up to 789,136 shares of the Company’s common stock at a price of $0.385 per share and/or 938,997 Warrants at a price of $0.01 per Warrant and/or 149,862 Pre-Funded Warrants at a price of $0.375 per Pre-Funded Warrant, or any combination of additional shares of common stock, Warrants and/or Pre-Funded Warrants, representing, in the aggregate, up to 15% of the number of Units sold in the offering, 15% of the Warrants underlying the Units and Pre-Funded Units sold in the offering and 15% of the Pre-Funded Warrants underlying the Pre-Funded Units sold in the offering, in all cases less the underwriting discount to cover over-allotments, if any. WallachBeth Capital LLC partially exercised its over-allotment option with respect to 818,177 Warrants on January 31, 2024, and purchased an additional 50 shares of common stock at a purchase price of $0.3750 and 50 Warrants at a purchase price of $0.01 on February 14, 2024. The Company also issued to WallachBeth Capital LLC warrants (the “January 2024 Representative Warrants”) to purchase 375,599 shares of the Company’s common stock, which is equal to 6% of the common stock sold that were part of the Units and the pre-funded warrants sold that were part of the Pre-Funded Units in the Offering, at an exercise price of $0.4235 per share (110% of the offering price per Unit). The January 2024 Representative Warrants may be exercised beginning on January 31, 2024 until January 31, 2029. The Units and Pre-Funded Units were offered and sold pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-276641), originally filed with the SEC on January 22, 2024 (the “January 2024 Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The January 2024 Registration Statement was declared effective by the SEC on January 29, 2024. The closing of the January 2024 Offering occurred on January 31, 2024. The net proceeds to the Company from the Offering were approximately $1.9 million, after deducting underwriting discounts and commissions and the payment of other offering expenses payable by the Company. On February 1, 2024, the Company issued 499,538 shares of common stock upon the exercise of 499,538 Pre-Funded Warrants, resulting in proceeds to the Company of $4,995. (b) Common Stock Warrants As of March 31, 2024, the Company accounts for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC 480 and ASC 815. On January 31, 2024, the Company executed a Warrant Agent Agreement with Equity Stock Transfer, LLC, acting as warrant agent for the January 2024 Offering (defined above), which sets forth the procedures for registering, transferring and exercising the Warrants and the Pre-Funded Warrants issued in connection with the January 2024 Offering. The Warrants and the Pre-Funded Warrants issued in the January 2024 Offering are accounted for as equity-classified financial instruments. There were no equity-classified warrants issued or outstanding during the three months ended March 31, 2023. The following table presents a summary of the activity for the Company’s equity-classified warrants during the three months ended March 31, 2024: Number of Weighted Weighted Total outstanding, December 31, 2023 3,163,854 $ 6.17 4.47 Granted 8,452,879 0.37 5.00 Exercised (499,538 ) 0.01 5.00 Forfeited - - - Expired - - - Total outstanding, March 31, 2024 11,117,195 $ 2.04 4.67 Total exercisable, March 31, 2024 11,117,195 $ 2.04 4.67 During the three months ended March 31, 2024, the Company received aggregate cash proceeds of $4,995 upon the exercise of 499,538 Pre-Funded Warrants with an exercise price of $0.01. The following table summarizes the significant assumptions used in determining the fair value of equity-classified warrants granted during the three months ended March 31, 2024: January 31, Stock price $ 0.28 Exercise price $ 0.42 Risk-free interest rate 3.91 % Expected volatility 95.00 % Expected term (years) 5.00 Expected dividend yield 0.00 % (c) Series A Preferred Stock The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Voting Rights Dividends Liquidation Rights - Conversion Rights

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt [Abstract]
DEBT	7. DEBT (a) Knight Therapeutics, Inc. On December 27, 2019 the Company restructured its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc. (“Knight”), into a note for the principal amount of $6,309,823 and accrued interest of $4,160,918 and a debenture of $3,483,851 (collectively, the “Knight Loan”). The Knight Loan had a maturity date of December 31, 2023. The principal and accrued interest portion of the Knight Loan bore an annual interest rate of 15%, compounded quarterly, whereas the debenture had a 9% interest rate until April 23, 2023 at which point interest ceased accruing. In January 2023, the Company and Knight executed the Knight Debt Conversion Agreement, pursuant to which the parties agreed to add a conversion feature to the cumulative outstanding Knight Loans, which was accounted for as a debt extinguishment, described further below. (b) Note, including Amendment The Company executed a promissory note (the “Note”) with an individual investor on October 11, 2017, later amended on December 11, 2022 (the “Amendment”). The Note, including the Amendment was set to mature 60 days after the Knight Loans were repaid, and contained a provision to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the Company consummated an IPO. Amortization of the discount on the Note, including the Amendment for the three months ended March 31, 2024 and 2023 was $0 and $24,145, respectively. Interest expense related to the Note, including the Amendment, for the three months ended March 31, 2024 and 2023 was $0 and $30,262, respectively. As a result of the completion of the IPO and as required under the terms of the Note, including the Amendment, the outstanding principal and accrued interest through March 31, 2022 converted to 214,934 shares of our common stock at a conversion rate equal to the IPO price, in full satisfaction of the outstanding debt obligation. As a result, as of March 31, 2024 and December 31, 2023 there were no amounts outstanding under the Note. (c) Convertible Promissory Notes and Warrants During May 2022 and May 2023 (the “2022 Bridge Notes” and “2023 Bridge Notes,” respectively), the Company executed promissory notes with various investors. The notes were due at the earlier of one year from the issuance date or the closing of an IPO. In connection with the issuance of the 2022 and 2023 Bridge Notes, the Company agreed to issue common stock to each noteholder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price. The Company performed an evaluation of the conversion features embedded in the 2022 and 2023 Bridge Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. Derivative liabilities are carried at fair value at each balance sheet date, and any changes in fair value are recognized in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). See Note 8 for further details. As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 303,982 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488, in full settlement of the outstanding debt obligations. As such, as of March 31, 2024 and December 31, 2023 there were no amounts outstanding under the 2022 and 2023 Bridge Notes. (d) Related Party Notes During May 2022, the Company executed convertible promissory notes with the Company’s Chief Executive Officer and a family member related to the Chief Executive Officer. The notes were due at the earlier of one-year (1) from the issuance date or the closing of an IPO, later extended an additional two months to July 2023 (the “Related Party Notes”). Upon the closing of the IPO, these notes were mandatorily convertible at a conversion rate determined at a 20% discount to the IPO price, discussed further below. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 90% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Related Party Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. See Note 8 for further details. As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 79,926 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding debt obligation. As such, as of March 31, 2024 and December 31, 2023 there were no amounts outstanding under the Related Party Notes. Significant terms of the Bridge Notes and Related Party Notes are summarized as follows: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3 1 - earlier of 1 year from date of issuance or closing of IPO, later extended to July 2023 2 - earlier of 1 year from date of issuance or closing of IPO 3 - see discussion above for (a) and (b) For the three months ended March 31, 2024 and 2023, the Company recorded amortization of debt discounts, including issuance costs, of $0 and $337,426, respectively. (e) Knight Debt Conversion On January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight’s debt in the event of an IPO. Key points of this agreement are as follows: ● The Parties agreed to fix Knight’s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original debt would resume including any interest earned after March 31, 2022. ● The Parties agreed to convert the fixed principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount equal to the offering price of the common stock in the IPO discounted by 15%, rounding up for fractional shares, in a number of common shares up to 19.9% of the Company’s outstanding common stock after giving effect of the IPO; (ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells Arakoda™ or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda™ or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January 21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda™ to include COVID-19 indications as well as malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith). ● The parties agreed to convert the accrued interest into that number of shares of a new class of preferred stock (the “Preferred Stock”) by dividing the fixed accumulated interest by $100.00, then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the shares of common stock in the initial public offering and (2) the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the Company’s sole discretion. Notwithstanding the foregoing, the Preferred Stock shall not be converted into shares of common stock if as a result of such conversion Knight will own 19.9% or more of our outstanding common stock. ● In addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the Closing or the conversion or redemption in full of the Preferred Stock, Company shall pay Lender a royalty equal to 3.5% of the Company’s net sales (the “Royalty”), where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine. Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight at the end of each calendar quarter. The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) business days after the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed following the above instructions, on the first calendar quarter in which the Qualified IPO takes place and will cover the sales for the period from January 1, 2022 until the end of said calendar quarter. The Company evaluated the January 9, 2023 exchange agreement in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. During the three months ended March 31, 2023, the Company recorded a loss upon extinguishment in the amount of $839,887 and elected to recognize the new debt under the ASC 825 fair value option until it was settled, which occurred in the third quarter of 2023 (see below). Therefore, there were no amounts outstanding as of March 31, 2024 or December 31, 2023. A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three months ended March 31, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 $ 21,815,841 As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. (f) Debenture On April 24, 2019, 60P entered into the Knight debenture of $3,000,000 with an original issue discount of $2,100,000, which was being amortized using the effective interest method. The Company subsequently restructured the Knight Loans, including the debenture, pursuant to the Knight Debt Conversion Agreement (see above). $13,696 of the original issue discount was amortized to interest expense during the three months ended March 31, 2023 prior to the amendment. The Knight Debt Conversion Agreement in January 2023 was accounted for as an extinguishment of the Debenture, as discussed above. Therefore, there were no amounts outstanding as of March 31, 2024 or December 31, 2023. (g) SBA COVID-19 EIDL On May 14, 2020, the Company received COVID-19 EIDL lending from the Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly basis. The balance as of March 31, 2024 and December 31, 2023 was $158,232 and $159,023, respectively. The current maturity at March 31, 2024 is $8,772 and the long-term liability is $149,460 ($8,772 and $150,251 at December 31, 2023, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA. The current future payment obligations of the principal are as follows: Period Principal 2024 (remaining nine months) $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000 Due to the deferral, the Company is expected to make a balloon payment of approximately $28,154 to be due on 10/12/2050.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2024
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities. As discussed in Note 7 above, certain of the Company’s bridge shares, warrants and convertible notes (containing an embedded conversion feature) were previously accounted for as derivative liabilities. The bridge shares and related conversion features were derecognized upon conversion of the related debt obligations on the date of the IPO. In addition, certain of the Company’s common stock warrants were previously accounted for as derivative liabilities as there was an unknown exercise price and number of shares associated with each instrument. In connection with the IPO, the terms of these warrants became fixed, at which point the Company determined the warrants met all of the criteria for equity classification and reclassified the warrants to additional paid-in capital at their fair value on the IPO date. As of March 31, 2024, derivative liabilities consist of the contingent milestone payment due to Knight upon a future sale of Arakoda™ or a Change of Control (See Note 7). The valuation of the contingent milestone payment includes significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three months ended March 31, 2024: Contingent Total Derivative liabilities - December 31, 2023 $ 2,306,796 $ 2,306,796 Fair value - mark to market adjustment (1,740,847 ) (1,740,847 ) Derivative liabilities - March 31, 2024 $ 565,949 $ 565,949 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three months ended March 31, 2023: Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ 1,499,334 Changes in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). During the three months ended March 31, 2024, the Company recorded a net change in the fair of derivative liabilities of ($1,740,847). During the three months ended March 31, 2023, the Company recorded a net change in the fair value of derivative liabilities of $5,134. Prior to the Company’s IPO, the fair value of the Company’s potential future issuances of common stock related to common stock issued with promissory notes, warrants and embedded conversion features in convertible promissory notes was established with an estimate using the Monte Carlo Simulation Model to compute fair value as of each reporting date. The Monte Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considered the probability of the occurrence or nonoccurrence of an IPO within the terms of liability-classified financial instruments, as an IPO could potentially impact the settlement.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Taxes [Abstract]
INCOME TAXES	9. INCOME TAXES The Company did not record a federal income tax provision or benefit for the three months ended March 31, 2024 and 2023 due to taxable losses. The Company recorded a provision for income taxes for DC of $63 for the three months ended March 31, 2024, thereby reflecting the minimum statutory tax due ($63 for the three months ended March 31, 2023).

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	10. SHARE-BASED COMPENSATION The following is a summary of share-based compensation expenses reported in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2024 and 2023: For the Three Months Ended 2024 2023 Research and Development $ - $ 87,658 General and Administrative Expenses 125,368 445,772 Total Share-Based Compensation Expense Included in Operating Expenses $ 125,368 $ 533,430 (a) Share-Based Compensation under 2022 Equity Incentive Plan On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. The 2022 Plan provides for an automatic increase in the number of shares available for issuance beginning on January 1, 2023 and each January 1 thereafter, by 4% of the number of outstanding shares of common stock on the immediately preceding December 31, or such number of shares as determined by the Board of Directors. As of March 31, 2024, the number of remaining shares available for issuance under the 2022 Plan is equal to 232,709. To date, the Company has granted shares of common stock, restricted stock units, stock options to employees, non-employees, and Directors under the 2022 Plan. For the three months ended March 31, 2024, the Company recognized $0 of compensation expense related to equity compensation awards granted under the 2022 Plan ($0 for the three months ended March 31, 2023). Awards Not Yet Granted The Company currently has compensation agreements with three executives and a consultant, which provide the individuals the right to an aggregate of 990,000 stock options, in each case the grant of the awards is subject to shareholder approval to increase the number of shares available under the 2022 Plan. 540,000 of these stock options are subject to vesting annually over five years with the first vesting date being December 31, 2024, and have an exercise price that was initially equal to the closing share price on the date of the IPO and later reduced to $1.00 per share, which reduction is also subject to shareholder approval in order to comply with Listing Rule 5635(c) of The Nasdaq Stock Market LLC. Pursuant to the Directors’ agreements described in Note 11, the agreements provide for the issuance of an aggregate of 37,736 stock options to Directors with an exercise price of $5.30 per share, vesting 100% on July 11, 2024. In February 2024, the Company executed an executive employment agreement with its Chief Commercial Officer that, subject to and upon receipt of shareholder approval, provides for the grant of stock options to purchase up to 250,000 shares of common stock, with an exercise price to be determined by the Board of Directors, and vesting over a five-year period. For accounting and disclosure purposes, no fair value has been ascribed to these stock option awards as no grant date (as defined in ASC 718) has been established. (b) Share-Based Payments to Vendors for Services During the three months ended March 31, 2024 and 2023, the Company issued 0 and 930,000 common stock shares, respectively, as share-based payments to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., in exchange for research and development services to be rendered to the Company in the future. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of fifteen months, work that was completed on May 3, 2024 (see Subsequent Events). Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. The Company recognizes prepaid research and development costs on the grant date, as defined in ASC 718. As of March 31, 2024, the unamortized balance of prepaid assets related to these share-based payments for research and development costs for which the grant date criteria has been met and the services are expected to be rendered within one year is $2,730,685 ($2,730,685 at December 31, 2023), which is presented as a component of Prepaid and Other Assets on the accompanying Consolidated Condensed Balance Sheets. In addition to share-based payments for research and development services, during the three months ended March 31, 2024 and 2023, 0 and 513,000 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. As of March 31, 2024, the unamortized balance of current prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $867,331 ($948,581 at December 31, 2023), which is reported in Prepaid and Other Assets on the Consolidated Condensed Balance Sheets. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $198,529 ($242,647 at December 31, 2023), reported in Long-Term Prepaid Expense on the Consolidated Condensed Balance Sheets. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. During the three months ended March 31, 2024 and 2023, the Company recorded $0 and $212,605, respectively, of share-based compensation expense in exchange for services provided by vendors. Amortization of capitalized share-based payments to vendors for the three months ended March 31, 2024 and 2023 was $125,368 and $320,825, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES (a) Operating Lease On February 3, 2016, and subsequently amended, the Company entered into the lease agreement with CXI Corp to rent business premises. In January 2023, the lease was extended for an additional twelve-month term, which expired on March 31, 2024. In December 2023, the Company executed an additional amendment with CXI Corp, pursuant to which the Company agreed to relocate to a new office space as of April 1, 2024. The term covered by the new amendment expires on March 31, 2025. The Company has accounted for the amendment for the new office space as a separate contract. As the initial term for the new office space is 12 months, the lease is not recorded on the balance sheet and the Company will recognize lease expense as short-term lease costs. Operating lease costs were in the amount of $14,053 and $13,507 for the three months ended March 31, 2024, and March 31, 2023, respectively. (b) Board of Directors In 2022, the Company signed agreements with its four Directors (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which came into effect on July 11, 2023, the date the Company’s IPO Registration Statement was declared effective. Each director is entitled to receive cash compensation of $11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee chair (Allen) will receive an additional $2,000 per quarter. In addition, each director is entitled to receive annual equity-based compensation awards, with the amounts and terms to be determined by the Compensation Committee. (c) Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. (d) Contingent Compensation Following the Company’s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note 7, the Company is obligated to pay Knight a contingent milestone payment of $10 million if the Company sells Arakoda™ or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note 8). On July 15, 2015, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the “U.S. Army”), which was subsequently amended (the “U.S. Army Agreement”), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or 20 years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of 3% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $35 million, and 5% of Net Sales greater than $35 million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones, including a sales-based milestone fee of $75,000 once cumulative Net Sales from all sources exceeds $6 million. The Company accrues the minimum annual royalty when the related sales occur. During the year ended December 31, 2023, the sales-based milestone target was achieved and therefore the Company has accrued a liability of $75,000 for the related milestone payment, which is reflected in Accounts Payable and Accrued Expenses at March 31, 2024 ($75,000 at December 31, 2023). The achievement of other milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made. (e) Litigation, Claims and Assessments From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 31, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events through May 15, 2024, which is the date the financial statements were issued. On April 1, 2024, the Company entered into an Amendment to the Debt Exchange Agreement with Trevally, LLC (“Trevally”), which amends the original agreement with Trevally (executed in January 2023). Pursuant to the Amendment, Trevally agreed to return 120,000 shares of the Company’s common stock, initially issued to Trevally in January 2023 as consideration for agreeing to complete the synthesis of research materials for the Company. Trevally has agreed to return the previously issued shares for no consideration and to complete the previously agreed services on or prior to June 30, 2024. On April 9, 2024, the Company issued 499,538 shares of common stock upon the exercise of 499,538 Pre-Funded Warrants, for aggregate cash proceeds to the Company of $4,995. On April 26, 2024, the U.S. Food and Drug Administration (FDA) provided comments on the Company’s protocol of its planned clinical trial that will study the use of tafenoquine in treating babesiosis, submitted to the FDA in February 2024. The FDA had questions and recommendations that will be addressed. The Company plans to continue preparatory actions to facilitate initiation of patient enrollment later in 2024. On May 3, 2024, the Company indicated to Kentucky Technology Inc, that their report on the potential development of SJ733 + tafenoquine, received on April 5, 2024, was acceptable to the Company. This report was delivered under the shares for services agreement between Kentucky Technology Inc. and the Company. There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 430,470	$ (2,600,061)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended December 31, 2023 and 2022, included in the Company’s annual report on Form 10-K, as filed with the SEC on April 1, 2024 (the “Annual Report”). Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Annual Report have been omitted.
Principles of Consolidation and Noncontrolling Interest	(b) Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated condensed financial statements.
Use of Estimates	(c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, derivative liabilities, and valuation allowance for the deferred tax asset.
Accounts Receivable and Allowance for Doubtful Accounts	(d) Accounts Receivable and Allowance for Doubtful Accounts The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company’s history there has been no need to make a recording to Allowance for Doubtful Accounts. Most of the Company’s revenue has been earned via government contracts, an Australian pharmaceutical distributor, and a large American pharmaceutical distributor. There was no allowance as of March 31, 2024 and December 31, 2023. As the Company continues to engage with smaller distributors, we will continue to analyze whether an allowance should be established. At March 31, 2024, the US government accounted for none of the outstanding accounts receivable balance (13% at December 31, 2023) and the American pharmaceutical distributor accounted for 99% of the outstanding accounts receivable balance (79% for the year ended December 31, 2023).
Inventory	(e) Inventory Inventories are stated at the lower of cost or net realizable value. Cost is comprised of direct materials and, where applicable, costs that have been incurred in bringing the inventories to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot number and sales are recognized by their lot number. The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to Cost of Revenues in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). During the three months ended March 31, 2024, write-downs for expired inventory totaled $641 ($5,391 for the three months ended March 31, 2023).
Derivative Liabilities	(f) Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of March 31, 2024, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date.
Equity-Classified Warrants	(g) Equity-Classified Warrants As of March 31, 2024, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.
Concentrations	(h) Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. At March 31, 2024, significant customers represented 99% of receivables (consisting of two customers and one significant customer at 99%). At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively). For the three months ended March 31, 2024, 90% of total net revenues (consisting of three customers and one significant customer at 90%) were generated from significant customers. For the three months ended March 31, 2023, 100% of total net revenues (consisting of two significant customers at 212% and (112%), respectively) were generated from significant customers. Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended in 2022 and near-term receivables and revenues from the government are not currently anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).
Business Segments	(i) Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach requires companies to report segment financial information consistent with information used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. A single management team that reports to the Chief Executive Officer comprehensively manages the business. Accordingly, since its inception, the Company has managed its business in one identifiable segment.
Revenue Recognition	(j) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. Revenues from product sales are recorded at the net sales price, or “transaction price,” which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company receives the majority of its revenues from sales of its Arakoda™ product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.
Research and Development Costs	(k) Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $337,182 in research and development expense during the three months ended March 31, 2024 ($123,994 for the three months ended March 31, 2023).
Fair Value of Financial Instruments and the Fair Value Option (“FVO”)	(l) Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Condensed Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss). Changes in fair value related to credit risk are recognized in Other Comprehensive Income (Loss). As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 7 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at March 31, 2024, and December 31, 2023 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 8 for more information on Derivative Liabilities. Liabilities measured at fair value at March 31, 2024 and December 31, 2023 are as follows: March 31, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 565,949 $ 565,949 Total $ - $ - $ 565,949 $ 565,949 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796 There were no transfers of financial instruments between Level 1, Level 2, and Level 3 during the periods presented. A rollforward of liabilities measured at fair value using Level 3 inputs for the three months ended March 31, 2024 and 2023 are presented in Note 7 (Debt) and Note 8 (Derivative Liabilities), respectively.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis	(m) Assets and Liabilities Not Measured at Fair Value on a Recurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the assets’ projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized. As of March 31, 2024, and December 31, 2023, the fair value of Cash and Cash Equivalents, Accounts Receivable, Prepaid Expenses and Other Current Assets, and Accounts Payable and Accrued Expenses approximated their carrying values due to the short-term nature of these assets and liabilities.
Foreign Currency Transactions and Translation	(n) Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements. For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as Unrealized Foreign Currency Translation Gain or Loss. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months ended As of Currency 2024 2023 March 31, December 31, 1 AUD = 0.66 USD 0.68 USD 0.65 USD 0.68 USD
Reclassifications	(o) Reclassifications Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive income (loss), shareholders’ equity (deficit), or cash flows.
Share-Based Payments	(p) Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 10. The Company accounts for share-based payments in accordance with ASC Subtopic 718, Compensation – Stock Compensation The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note 10 for further details.
Leases	(q) Leases The Company applies ASC Topic 842, Leases The Company determines if an arrangement is a lease at contract inception. The Company’s contracts are determined to contain a lease when all of the following criteria, based on the specific circumstances of the arrangement, are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset. At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreement does not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate (“IBR”), to discount lease payments, which represents the rate of interest the Company would pay to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.
Net Income (Loss) per Common Share	(r) Net Income (Loss) per Common Share Net Income (Loss) per Common Share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company has included the Pre-Funded Warrants issued in January 2024 (See Note 6) in its computation of basic and diluted net income (loss) per share due to the nominal exercise price of $0.01 per share. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an addition to net loss or a reduction of net income in determining basic and diluted net income (loss) attributable to common stockholders. As the Company reported a net loss for the three months ended March 31, 2023, the calculation of diluted net loss per common share is the same as basic net loss per common share. For the three months ended March 31, 2024, all securities that could potentially dilute basic earnings per share in the future have been excluded from the diluted calculation because the effect would be antidilutive. The potential dilutive securities for the three months ended March 31, 2024 include 10,617,657 common stock warrants and 37,736 unexercised stock options granted under the 2022 Plan.
Related Parties	(s) Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Subsequent Events	(t) Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through May 15, 2024, which is the date the financial statements were issued. See Note 12.
Recently Adopted and Issued Accounting Pronouncements	(u) Recently Adopted and Issued Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company’s financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. The ASU also requires entities with a single reportable segment to provide all segment disclosures under ASC 280, including the new required disclosures under the ASU. The ASU is effective for all public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The ASU must be applied retrospectively. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statement disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Liabilities Measured at Fair Value	Liabilities measured at fair value at March 31, 2024 and December 31, 2023 are as follows: March 31, 2024 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 565,949 $ 565,949 Total $ - $ - $ 565,949 $ 565,949 December 31, 2023 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 2,306,796 $ 2,306,796 Total $ - $ - $ 2,306,796 $ 2,306,796
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements	Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months ended As of Currency 2024 2023 March 31, December 31, 1 AUD = 0.66 USD 0.68 USD 0.65 USD 0.68 USD

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory [Abstract]
Schedule of Inventory	Inventory consists of the following major classes: March 31, December 31, Work in Process $ 278,987 $ 278,987 Finished Goods 156,390 187,182 Inventory 435,377 466,169

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Property and Equipment [Abstract]
Schedule of Property and Equipment	As of March 31, 2024 and December 31, 2023, Property and Equipment, net consists of: March 31, December 31, 2024 2023 Lab Equipment $ 132,911 $ 132,911 Machinery 55,800 55,800 Computer Equipment 14,084 14,084 Furniture 3,030 3,030 Property and Equipment, at cost 205,825 205,825 Accumulated Depreciation (148,471 ) (148,064 ) Property and Equipment, Net $ 57,354 $ 57,761

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Intangible Assets [Abstract]
Schedule of Intangible Assets	As of March 31, 2024 and December 31, 2023, Intangible Assets, net consist of: March 31, December 31, Patents $ 174,614 $ 185,595 Website Development Costs 88,336 79,248 Intangible Assets, at cost 262,950 264,843 Accumulated Amortization (45,533 ) (37,585 ) Intangible Assets, net $ 217,417 $ 227,258
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	The following table summarizes the estimated future amortization expense for our patents and website development costs as of March 31, 2024: Period Patents Website 2024 (remaining nine months) $ 4,959 $ 19,812 2025 6,612 23,303 2026 6,612 3,974 2027 6,612 - Thereafter 55,279 - Total $ 80,074 $ 47,089

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity [Abstract]
Schedule of Equity Classified Warrants	There were no equity-classified warrants issued or outstanding during the three months ended March 31, 2023. The following table presents a summary of the activity for the Company’s equity-classified warrants during the three months ended March 31, 2024: Number of Weighted Weighted Total outstanding, December 31, 2023 3,163,854 $ 6.17 4.47 Granted 8,452,879 0.37 5.00 Exercised (499,538 ) 0.01 5.00 Forfeited - - - Expired - - - Total outstanding, March 31, 2024 11,117,195 $ 2.04 4.67 Total exercisable, March 31, 2024 11,117,195 $ 2.04 4.67
Schedule of Assumptions Used In Determining the Fair Value of Equity Classified Warrants on the Respective Grant	The following table summarizes the significant assumptions used in determining the fair value of equity-classified warrants granted during the three months ended March 31, 2024: January 31, Stock price $ 0.28 Exercise price $ 0.42 Risk-free interest rate 3.91 % Expected volatility 95.00 % Expected term (years) 5.00 Expected dividend yield 0.00 %

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt [Abstract]
Schedule of Bridge Notes and Related Party Notes	Significant terms of the Bridge Notes and Related Party Notes are summarized as follows: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 2 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 3 3 3
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note	A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three months ended March 31, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 $ 21,815,841
Schedule of the Current Future Payment Obligations	The current future payment obligations of the principal are as follows: Period Principal 2024 (remaining nine months) $ - 2025 - 2026 683 2027 3,228 2028 3,342 Thereafter 142,747 Total $ 150,000

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Derivative Liabilities [Abstract]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis	A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three months ended March 31, 2024: Contingent Total Derivative liabilities - December 31, 2023 $ 2,306,796 $ 2,306,796 Fair value - mark to market adjustment (1,740,847 ) (1,740,847 ) Derivative liabilities - March 31, 2024 $ 565,949 $ 565,949 Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ 1,499,334

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Compensation [Abstract]
Schedule of Share-Based Compensation Expenses	The following is a summary of share-based compensation expenses reported in the Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2024 and 2023: For the Three Months Ended 2024 2023 Research and Development $ - $ 87,658 General and Administrative Expenses 125,368 445,772 Total Share-Based Compensation Expense Included in Operating Expenses $ 125,368 $ 533,430

Nature of Operations (Details)

Nature of Operations (Details) - USD ($)				3 Months Ended		12 Months Ended
	Jan. 29, 2024	Jul. 14, 2023	Jul. 13, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 14, 2024
Nature of Operations [Line Items]
Price per unit	$ 0.01			$ 0.01
Net proceeds (in Dollars)				$ 1,914,513
Common stock, par value				$ 0.0001		$ 0.0001
Exercise price per share	$ 0.4235			$ 0.01			$ 0.01
Percentage of offering price per unit	110%		110%	110%
Cash and cash equivalents (in Dollars)				$ 2,894,700
Net cash used in operating activities (in Dollars)				(1,140,438)	$ (412,678)
Company’s debt (in Dollars)				8,772		$ 8,772
Operating lease liabilities (in Dollars)				$ 529,449
Cash [Member]
Nature of Operations [Line Items]
Cash and cash equivalents (in Dollars)						2,142,485
Initial Public Offering [Member]
Nature of Operations [Line Items]
Initial public offering shares (in Shares)		1,415,095
Price per unit		$ 5.3
Net proceeds (in Dollars)		$ 6,454,325				$ 7,000,000
Common stock, par value		$ 0.0001
Tradeable Warrants [Member]
Nature of Operations [Line Items]
Price per unit				$ 0.01
Exercise price per share		6.095
Purchase of shares (in Shares)			100,644	212,265
Non-Tradeable Warrants [Member]
Nature of Operations [Line Items]
Price per unit				$ 0.01
Exercise price per share		$ 6.36
Warrants expire term		5 years
Purchase of shares (in Shares)			100,644	212,265
Over-Allotment Option [Member]
Nature of Operations [Line Items]
Price per unit				$ 5.28
Purchase of shares (in Shares)				212,265
Representative Warrants [Member]
Nature of Operations [Line Items]
Price per unit			$ 5.83
Purchase of shares (in Shares)			84,906
Representative warrants exercisable term			5 years

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		12 Months Ended
	Aug. 02, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jan. 29, 2024
Summary of Significant Accounting Policies [Line Items]
Common stock shares (in Shares)		0	930,000
Consolidated owner percentage		100%
Outstanding accounts receivable balance rate		79%
Inventory write-downs (in Dollars)		$ 641	$ 5,391
Research and development costs (in Dollars)		$ 337,182	$ 123,994
Exercise price per share (in Dollars per share)		$ 0.01			$ 0.01
Common stock warrant shares (in Dollars per share)		10,617,657
Unexercised stock options (in Dollars per share)		$ 37,736
US Government Accounted [Member]
Summary of Significant Accounting Policies [Line Items]
Outstanding accounts receivable balance rate		13%
American Pharmaceutical Distributor [Member]
Summary of Significant Accounting Policies [Line Items]
Outstanding accounts receivable balance rate		99%
Single Customers One [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		99%
Single Customers Two [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		99%
Single Customers Three [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		92%
Single Customers Four [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		90%
Receivable [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		90%
Australia Pty Ltd [Member] | Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage	87.53%
Australia Pty Ltd [Member] | Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Proportional ownership percentage	96.61%
Customer [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		10%
Customer One [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		212%		79%
Customer Two [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		112%		13%
Significant Customers [Member] | Revenue from Rights Concentration Risk [Member] | Revenue Benchmark [Member]
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage		100%
Australia Pty Ltd [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock shares (in Shares)	904,436

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Liabilities Measured at Fair Value - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities	$ 565,949	$ 2,306,796
Total	565,949	2,306,796
Level 1 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities
Total
Level 2 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities
Total
Level 3 [Member]
Schedule of Liabilities Measured at Fair Value [Line Items]
Derivative Liabilities	565,949	2,306,796
Total	$ 565,949	$ 2,306,796

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Average Exchange Rates			3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
AUD [Member]
Summary of Significant Accounting Policies (Details) - Schedule of Average Exchange Rates [Line Items]
Average Exchange Rate	0.65%	0.68%	0.66%	0.68%

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Inventory [Abstract]
Work in Process	$ 278,987	$ 278,987
Finished Goods	156,390	187,182
Inventory	$ 435,377	$ 466,169

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property and Equipment [Abstract]
Machinery total	$ 55,800
Depreciation expenses	$ 407	$ 6,901

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	$ 205,825	$ 205,825
Accumulated Depreciation	(148,471)	(148,064)
Property and Equipment, Net	57,354	57,761
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	132,911	132,911
Machinery [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	55,800	55,800
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	14,084	14,084
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at cost	$ 3,030	$ 3,030

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Intangible Assets [Line Items]
Development related costs	$ 9,088	$ 33,895
Amortization	8,207	7,175
Write-offs of capitalized patents	8,378
Capitalized patent expenses	83,830
Website Development [Member]
Intangible Assets [Line Items]
Development related costs	$ 9,088

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Intangible Assets [Abstract]
Patents	$ 174,614	$ 185,595
Website Development Costs	88,336	79,248
Intangible Assets, at cost	262,950	264,843
Accumulated Amortization	(45,533)	(37,585)
Intangible Assets, net	$ 217,417	$ 227,258

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	Mar. 31, 2024 USD ($)
Patents [Member]
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2024 (remaining nine months)	$ 4,959
2025	6,612
2026	6,612
2027	6,612
Thereafter	55,279
Total	80,074
Website Development Costs [Member]
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2024 (remaining nine months)	19,812
2025	23,303
2026	3,974
2027
Thereafter
Total	$ 47,089

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)						3 Months Ended
	Feb. 14, 2024	Feb. 01, 2024	Jan. 29, 2024	Jul. 13, 2023	Jun. 30, 2022	Mar. 31, 2024	Jan. 31, 2024	Dec. 31, 2023	Jul. 14, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022
Stockholders’ Equity [Line Items]
Common stock shares authorized						150,000,000		150,000,000
Common stock par value (in Dollars per share)						$ 0.0001		$ 0.0001
Common stock, shares issued						11,762,578		5,810,089
Common stock, shares outstanding						11,762,578		5,810,089
Percentage of shares issued and outstanding												61%
Public offering units (in Dollars)			$ 5,260,901
Warrant offering price (in Dollars per share)			$ 0.385
Exercise price of warrants (in Dollars per share)	$ 0.01		$ 0.4235			$ 0.01
Offering price per unit			110%	110%		110%
Price per share (in Dollars per share)			$ 0.01			$ 0.01
Pre funded warrant (in Dollars per share)			0.01
Warrants exercise (in Dollars)						$ 938,997
Pre-Funded Warrant						149,862
Percentage of warrant units sold						15%
Percentage of warrant underlying the pre funded units sold						15%
Percentage of Pre funded warrant underlying the pre funded unit sold						15%
Additional common share	50
Sale of stock price per share (in Dollars per share)	$ 0.375
Exercise of warrants	50					499,538
Net proceeds (in Dollars)						$ 1,900,000
Warrants proceeds (in Dollars)		$ 4,995
Warrants with an exercise price (in Dollars per share)						$ 37,736
Dividends percentage						6%
Dividends preferred stock (in Dollars)						$ 338,595
Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Warrant offering price (in Dollars per share)			$ 0.375
Pre funded warrant units			999,076
Number of shares			1
Number of warrant exercisable			1
Warrant [Member]
Stockholders’ Equity [Line Items]
Number of shares			1
Number of warrant exercisable			1
Pre funded warrant (in Dollars per share)						$ 0.375
January 2024 Representative Warrants [Member]
Stockholders’ Equity [Line Items]
Prefunded warrants sold percentage					6%
Bridge Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise of warrants						4,995
Tradeable Warrants [Member]
Stockholders’ Equity [Line Items]
Warrants with an exercise price (in Dollars per share)						$ 0.01
60 Degrees Pharmaceuticals, Inc. [Member]
Stockholders’ Equity [Line Items]
Common stock shares authorized						150,000,000
Common stock par value (in Dollars per share)						$ 0.0001
Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized						1,000,000
Preferred stock shares, par value (in Dollars per share)						$ 0.0001
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued		499,538				11,762,578
Common stock, shares outstanding						11,762,578
Number of shares			1
Exercise of warrants		499,538
Common Stock [Member] | Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Number of shares			1
Common Stock [Member] | January 2024 Representative Warrants [Member]
Stockholders’ Equity [Line Items]
Purchase of common shares						375,599
Tyrone Miller [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued										192,101	192,101
Geoffrey S. Dow [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued										1,258,899	1,258,899
Vendors [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued										1,443,000	1,443,000
Chief Executive Officer [Member]
Stockholders’ Equity [Line Items]
Price per share (in Dollars per share)					$ 0.4235
Series A Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized						1,000,000		1,000,000
Preferred stock shares, par value (in Dollars per share)						$ 0.0001		$ 0.0001
Designated shares						80,965
Preferred stock shares outstanding						78,803		78,803
Preferred stock shares issued						78,803		78,803
Dividends percentage						19.90%
Dividends preferred stock (in Dollars)						$ 117,881
Preferred stock converted shares (in Dollars per share)						$ 100
Description of conversion term						The “Conversion Price” is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company’s IPO, or (c) the 10-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.
IPO [Member]
Stockholders’ Equity [Line Items]
Common stock par value (in Dollars per share)									$ 0.0001
Price per share (in Dollars per share)									$ 5.3
Purchase of granted shares						789,136
Purchased share price (in Dollars per share)						$ 0.385
Over-Allotment Option [Member]
Stockholders’ Equity [Line Items]
Price per share (in Dollars per share)						$ 5.28
Warrants exercise (in Dollars)							$ 818,177

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of Equity Classified Warrants - Warrants [Member] - $ / shares		3 Months Ended
	Dec. 31, 2023	Mar. 31, 2024
Schedule of Equity-Classified Warrants [Line Items]
Number of Warrants, Total outstanding, Ending	3,163,854	11,117,195
Weighted Average Exercise Price, Total outstanding, Ending	$ 6.17	$ 2.04
Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending	4 years 5 months 19 days	4 years 8 months 1 day
Number of Warrants,Total exercisable, December 31, 2023		11,117,195
Weighted Average Exercise Price,Total exercisable, December 31, 2023		$ 2.04
Weighted Average Remaining Contractual Life (Years),Total exercisable, December 31, 2023		4 years 8 months 1 day
Number of Warrants, Granted		8,452,879
Weighted Average Exercise Price, Granted		$ 0.37
Weighted Average Remaining Contractual Life (Years), Granted		5 years
Number of Warrants, Exercised		(499,538)
Weighted Average Exercise Price, Exercised		$ 0.01
Weighted Average Remaining Contractual Life (Years), Exercised		5 years
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited
Number of Warrants, Expired
Weighted Average Exercise Price, Expired

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of Assumptions Used In Determining the Fair Value of Equity Classified Warrants on the Respective Grant - Minimum [Member]	Jan. 31, 2024 $ / shares
Schedule of Assumptions Used In Determining the Fair Value of Equity Classified Warrants on the Respective Grant [Line Items]
Stock price (in Dollars per share)	$ 0.28
Exercise price (in Dollars per share)	$ 0.42
Risk-free interest rate	3.91%
Expected volatility	95%
Expected term (years)	5 years
Expected dividend yield	0%

Debt (Details)

Debt (Details) - USD ($)				3 Months Ended		12 Months Ended
	Jul. 14, 2023	Mar. 31, 2022	Dec. 27, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Apr. 23, 2023	May 14, 2020	Apr. 24, 2019
Debt [Line Items]
Debenture									$ 3,000,000
Amortization discount				$ 0	$ 24,145
Interest expense		$ 214,934		$ 0
Vested warrants				5 years
Common stock shares issued (in Shares)				11,762,578		5,810,089
Outstanding debt obligations.					1,749,488
Conversion rate, percentage				80%
Converted shares (in Shares)		1,108,337		79,926
Gross proceeds				$ 1,914,513
Initial public offering discount, percentages				15%
Common stock outstanding, percentages				19.90%
Milestone payment				$ 10,000,000
Regulatory advice value				$ 30,000
Cumulative dividend				6%
Common stock ownership percentage				19.90%
Equal royalty pay to lender, percentage				$ 3.5
Extinguishment loss					839,887
Debt issuance costs									2,100,000
Long term liability				8,772		$ 8,772
Current maturity				149,460
Long-term liability				$ 149,460		150,251
Knight Therapeutics, Inc. [Member]
Debt [Line Items]
Principal amount			$ 6,309,823
Accrued interest			4,160,918
Debenture			$ 3,483,851
Annual interest rate							15%
Debenture interest rate							9%
Note [Member]
Debt [Line Items]
Interest expense					30,262
2022 Bridge Notes [Member]
Debt [Line Items]
Face amount, percentage				100%
Balloon payment				$ 28,154
2023 Bridge Notes [Member]
Debt [Line Items]
Amortization discount				0	$ 337,426
Knight’s Cumulative Debt [Member]
Debt [Line Items]
Principal amount		$ 10,770,037
Accumulated interest		$ 8,096,486
Debenture [Member]
Debt [Line Items]
Amortized interest expense									$ 13,696
Small Business Administration [Member]
Debt [Line Items]
Principal amount								$ 150,000
Annual interest rate								3.75%
Principal payments				158,232		159,023
Preferred Stock [Member]
Debt [Line Items]
Accumulated interest				100
Knight Debt [Member]
Debt [Line Items]
Ownership percentage		19.90%
Series A Preferred Stock [Member]
Debt [Line Items]
Converted shares (in Shares)		80,965
IPO [Member]
Debt [Line Items]
Accrued interest				$ 31,968
Vested warrants				1 year
Fully vested warrants exercise price percentage				110%
Conversion rate, percentage				20%
Gross proceeds	$ 6,454,325					$ 7,000,000
IPO [Member] | Bridge Notes [Member]
Debt [Line Items]
Common stock shares issued (in Shares)				303,982
IPO [Member] | Chief Executive Officer [Member]
Debt [Line Items]
Conversion rate, percentage				90%

Debt (Details) - Schedule of Br

Debt (Details) - Schedule of Bridge Notes and Related Party Notes	3 Months Ended
	Mar. 31, 2024
2022 Bridge Notes [Member]
Related Party Transaction [Line Items]
Issuance date of promissory notes	May 2022
Maturity date of promissory notes	1
Interest rate	10%
Default interest rate	15%
Collateral	Unsecured
Conversion rate	3
Related Party Notes [Member]
Related Party Transaction [Line Items]
Issuance date of promissory notes	May 2022
Maturity date of promissory notes	1
Interest rate	6%
Default interest rate	15%
Collateral	Unsecured
Conversion rate	3
2023 Bridge Notes [Member]
Related Party Transaction [Line Items]
Issuance date of promissory notes	May 2023
Maturity date of promissory notes	2
Interest rate	10%
Default interest rate	15%
Collateral	Unsecured
Conversion rate	3

Debt (Details) - Schedule of Re

Debt (Details) - Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note [Abstract]
Promissory Notes, at fair value at December 31, 2022
Fair value at modification date - January 9, 2023	21,520,650
Fair value - mark to market adjustment	(339,052)
Accrued interest recognized	634,243
Promissory Notes, at fair value at March 31, 2023	$ 21,815,841

Debt (Details) - Schedule of th

Debt (Details) - Schedule of the Current Future Payment Obligations	Mar. 31, 2024 USD ($)
Schedule of the Current Future Payment Obligations [Abstract]
2024 (remaining nine months)
2025
2026	683
2027	3,228
2028	3,342
Thereafter	142,747
Total	$ 150,000

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Derivative Liabilities [Line Items]
Fair of derivative liabilities	$ 1,740,847	$ 5,134

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning	$ 2,306,796	$ 1,494,200
Fair value - mark to market adjustment	(1,740,847)	5,134
Derivative liabilities - Ending	565,949	1,499,334
Contingent Milestone Payment [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning	2,306,796
Fair value - mark to market adjustment	(1,740,847)
Derivative liabilities - Ending	$ 565,949
Bridge Shares [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		834,352
Fair value - mark to market adjustment		4,902
Derivative liabilities - Ending		839,254
Warrants [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		578,164
Fair value - mark to market adjustment		1,689
Derivative liabilities - Ending		579,853
Convertible Notes Payable [Member]
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Derivative liabilities - Beginning		81,684
Fair value - mark to market adjustment		(1,457)
Derivative liabilities - Ending		$ 80,227

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Taxes [Abstract]
Income taxes	$ 63	$ 63

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)		3 Months Ended		12 Months Ended
	Jul. 11, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 29, 2024
Share-Based Compensation (Details) [Line Items]
Percentage of outstanding shares of common stock				4%
Remaining shares available for issuance (in Shares)		232,709
Compensation expense		$ 867,331		$ 948,581
Aggregate of stock options (in Shares)		990,000
Stock options are subject to vesting (in Shares)		540,000
Vesting period		5 years
Shares of common stock exercise price (in Shares)					250,000
Common stock shares issued (in Shares)		0	930,000
Share issued as fully vested (in Shares)		0	513,000
Long-Term Prepaid Expense		$ 198,529		242,647
Share-based compensation expense			$ 212,605
Amortization of capitalized share-based payments		125,368	320,825
Restricted Stock Units [Member]
Share-Based Compensation (Details) [Line Items]
Compensation expense		0	$ 0
Share-based compensation expense		0
Research and Development [Member]
Share-Based Compensation (Details) [Line Items]
Compensation expense		$ 2,730,685		$ 2,730,685
Forecast [Member]
Share-Based Compensation (Details) [Line Items]
Share price (in Dollars per share)	$ 5.3
Percentage of vested	100%
Forecast [Member] | Director [Member]
Share-Based Compensation (Details) [Line Items]
Aggregate of stock options (in Shares)	37,736
IPO [Member]
Share-Based Compensation (Details) [Line Items]
Share price (in Dollars per share)		$ 1

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of Share-Based Compensation Expenses - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Share-Based Compensation Expenses [Abstract]
Research and Development		$ 87,658
General and Administrative Expenses	125,368	445,772
Total Share-Based Compensation Expense Included in Operating Expenses	$ 125,368	$ 533,430

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)		3 Months Ended
	Jul. 15, 2015	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Commitments and Contingencies [Line Items]
Operating lease costs		$ 14,053	$ 13,507
Licensed technology term.	20 years
Annual royalty payment	5%
Sales-based milestone fee	$ 75,000
Cumulative net sales	6,000,000
Accrued liability			$ 75,000	$ 75,000
US Government Sales [Member]
Commitments and Contingencies [Line Items]
Royalty expense	35,000,000
U.S. Army Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty expense	$ 35,000,000
Board of Directors Chairman [Member]
Commitments and Contingencies [Line Items]
Annual royalty payment	3%
Board of Directors Chairman [Member] | Cheryl Xu [Member]
Commitments and Contingencies [Line Items]
Cash compensation		11,250
Board of Directors Chairman [Member] | Paul Field [Member]
Commitments and Contingencies [Line Items]
Cash compensation		11,250
Board of Directors Chairman [Member] | Paul Field [Member] | Non-Audit Committee [Member]
Commitments and Contingencies [Line Items]
Cash compensation		1,250
Board of Directors Chairman [Member] | Charles Allen [Member]
Commitments and Contingencies [Line Items]
Cash compensation		11,250
Board of Directors Chairman [Member] | Charles Allen [Member] | Audit Committee [Member]
Commitments and Contingencies [Line Items]
Cash compensation		2,000
Board of Directors Chairman [Member] | Stephen Toovey [Member]
Commitments and Contingencies [Line Items]
Cash compensation		11,250
Board of Directors Chairman [Member] | Stephen Toovey [Member] | Non-Audit Committee [Member]
Commitments and Contingencies [Line Items]
Cash compensation		1,250
IPO [Member]
Commitments and Contingencies [Line Items]
Payment		$ 10,000,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Apr. 09, 2024	Apr. 01, 2024
Subsequent Events [Line Items]
Underwriting agreement		120,000
Pre-funded warrants	499,538
Warrants shares	499,538
Warrants proceeds (in Dollars)	$ 4,995